- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Fate Therapeutics (FATE)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 50.85 mm | 50.85 mm | 50.85 mm | 50.85 mm | 50.85 mm | 50.85 mm |
| Cash burn (monthly) | 209.00 k | (no burn) | 11.58 mm | 14.56 mm | 8.12 mm | 9.21 mm |
| Cash used (since last report) | 495.12 k | n/a | 27.43 mm | 34.49 mm | 19.25 mm | 21.83 mm |
| Cash remaining | 50.35 mm | n/a | 23.42 mm | 16.35 mm | 31.60 mm | 29.02 mm |
| Runway (months of cash) | 240.9 | n/a | 2.0 | 1.1 | 3.9 | 3.1 |
| 13F holders | Current |
|---|---|
| Total holders | 159 |
| Opened positions | 37 |
| Closed positions | 39 |
| Increased positions | 44 |
| Reduced positions | 48 |
| 13F shares | Current |
|---|---|
| Total value | 162.57 bn |
| Total shares | 106.52 mm |
| Total puts | 15.90 k |
| Total calls | 41.30 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Redmile | 12.87 mm | $21.24 bn |
| BlackRock | 10.94 mm | $18.05 bn |
| Vanguard | 10.33 mm | $17.05 bn |
| Boxer Capital Management | 4.96 mm | $13.10 mm |
| BLVGF Bellevue | 4.84 mm | $7.99 bn |
| Citadel Advisors | 4.38 mm | $7.23 bn |
| Deerfield Management | 3.56 mm | $5.87 bn |
| JNJ Johnson & Johnson | 3.38 mm | $5.58 bn |
| Baker Bros. Advisors | 3.26 mm | $5.38 bn |
| EcoR1 Capital | 3.05 mm | $5.03 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Oct 25 | Kamal Adawi | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 75,000 |
| 20 Oct 25 | Kamal Adawi | Stock Option Common Stock | Grant | Acquire A | No | No | 1.54 | 375,000 | 577.50 k | 375,000 |
| 4 Aug 25 | Bahram Valamehr | Common Stock | Sell | Dispose S | No | No | 1.0643 | 14,466 | 15.40 k | 334,898 |
| 4 Aug 25 | Cindy Tahl | Common Stock | Sell | Dispose S | No | No | 1.0593 | 9,037 | 9.57 k | 397,670 |